Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Novavax, Inc.

SG&A Expenses: Regeneron vs. Novavax Over a Decade

__timestampNovavax, Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 201419928000504755000
Thursday, January 1, 201530842000838526000
Friday, January 1, 2016465270001177697000
Sunday, January 1, 2017344510001320433000
Monday, January 1, 2018344090001556200000
Tuesday, January 1, 2019344170001834800000
Wednesday, January 1, 20201452900001346000000
Friday, January 1, 20212983580001824900000
Saturday, January 1, 20224886910002115900000
Sunday, January 1, 20234689460002631300000
Monday, January 1, 20242954400000
Loading chart...

In pursuit of knowledge

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, understanding the financial strategies of industry leaders is crucial. Regeneron Pharmaceuticals, Inc. and Novavax, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Regeneron, a giant in the field, consistently outspent Novavax, with its SG&A expenses peaking at approximately $2.63 billion in 2023, a staggering 460% increase from 2014. In contrast, Novavax's expenses grew more modestly, reaching around $469 million in 2023, marking a 2,256% increase from its 2014 figures. This disparity highlights Regeneron's aggressive investment in administrative and sales functions, possibly reflecting its expansive market reach and product portfolio. Meanwhile, Novavax's leaner approach may indicate a focus on strategic growth and innovation. These financial trajectories offer a window into each company's operational priorities and market strategies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025